臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52722206 線上人數 : 668 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c h"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 866-875 / 1656 (共166頁)
<< < 82 83 84 85 86 87 88 89 90 91 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2020-04-10T12:51:23Z	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment	Yang C.-H.; Yang P.-C.; Cheng A.-L.; Lin C.-C.; Hsu C.-H.; Yu C.-J.; Chang Y.-C.; Chiun Hsu; Lin Z.-Z.
臺大學術典藏	2020-04-10T12:51:21Z	Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway	Chen K.-F.; Yeh P.-Y.; Chiun Hsu; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:21Z	The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma	Lin Z.-Z.;Hsu H.-C.;Hsu C.-H.;Yeh P.-Y.;Huang C.-Y.F.;Huang Y.-F.;Chen T.-J.;Kuo S.-H.;Chiun Hsu;Hu F.-C.;Jeng Y.-M.;Chung Y.;Cheng A.-L.; Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Chiun Hsu; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:20Z	Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma	Hsu C.-H.;Yang T.-S.;Chiun Hsu;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; Hsu C.-H.; Yang T.-S.; Chiun Hsu; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:19Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Hsu C.-H.;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Chiun Hsu;Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Chiun Hsu; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:17Z	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	Shao Y.-Y.;Lin Z.-Z.;Chiun Hsu;Shen Y.-C.;Hsu C.-H.;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:16Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Chiun Hsu ;Shen Y.-C. ;Hsu C.-H. ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:16Z	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil	Hsu C.-H.; Hu F.-C.; Hsu C.-Y. ;Shen Y.-C. ;Yu C.-W. ;Chiun Hsu ;Hu F.-C. ;Hsu C.-H. ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F.; Hsu C.-Y.; Shen Y.-C.; Yu C.-W.; Chiun Hsu; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.
臺大學術典藏	2020-04-10T12:51:15Z	Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials	Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Chiun Hsu; Hsu C.-H.; Kuo S.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:15Z	Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma	Cheng A.-L.; Hsu C.-H.; Lin Z.-Z.; Chiun Hsu; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Shao Y.-Y.

顯示項目 866-875 / 1656 (共166頁)
<< < 82 83 84 85 86 87 88 89 90 91 > >>
每頁顯示[10|25|50]項目